← Leaderboards
Justin C McArthur
Johns Hopkins University
$21,339,205
Attributed
$21,418,585
Total exposure
40
Grants
24
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $4.1M · FY2005–19$5M$3.8M$2.5M$1.3M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
Funding mix
By agency
NIH$50,513,431 · 43
By mechanism
P30$31,074,915 · 7
P01$10,180,439 · 5
R01$4,841,970 · 2
R25$2,332,652 · 1
M01$1,077,997 · 25
T32$780,601 · 1
Top collaborators
- Norman J Haughey5 shared
- Glenn J Treisman2 shared
Most similar at Johns Hopkins University
Same institution · by research overlap
- Joseph B. Margolick$86,818,342
- M Christine Zink$22,445,266
- Richard E Chaisson$50,014,616
- Suzanne Gartner$7,702,037
- Stuart S Martin$11,571,187
Others in their field
Top investigators on “Clinical Research”
- David Heimbrook · Leidos Biomedical Research, Inc.$1,040,569,537
- Leonard Freedman · Leidos Biomedical Research, Inc.$975,089,882
- Lawrence Corey · Fred Hutchinson Cancer Center$739,766,552
- Sonia M Thomas · Research Triangle Institute$700,865,642
- Jeffrey P Krischer · University Of South Florida$611,867,176
- Barton F Haynes · Duke University$538,862,577
Research focus
Clinical ResearchResearch PersonnelFundingHuman SubjectBaseHiv InfectionsAids /Hiv NeuropathyResourcesInnovationNovel TherapeuticsAids Dementia ComplexClinical TrialsCognition DisordersProgramsNeurologicCollaborationsGrantHuman Therapy EvaluationImpaired CognitionAcquired Immunodeficiency SyndromeInstitutionUnited States National Institutes Of HealthCohortMonitor
Grant awards (138)
JHU NIMH Center for Novel Therapeutics for HIV-associated Cognitive Disorders$1,474,165
P30 · FY2019 · MH · contact PI
'Intranasal Insulin Therapy for HIV- Associated Neurocognitive Disorders'$1,303,885
P01 · FY2019 · MH · contact PI
Translational Research in Neuro-AIDS and Mental Health$230,261
R25 · FY2019 · MH · contact PI
Administrative Core$178,150
P30 · FY2019 · MH · contact PI
Administrative Core$142,210
P01 · FY2019 · MH · contact PI
JHU NIMH Center for Novel Therapeutics for HIV-associated Cognitive Disorders$1,490,939
P30 · FY2018 · MH · contact PI
'Intranasal Insulin Therapy for HIV- Associated Neurocognitive Disorders'$1,331,146
P01 · FY2018 · MH · contact PI
Translational Research in Neuro-AIDS and Mental Health$232,961
R25 · FY2018 · MH · contact PI
Administrative Core$184,060
P30 · FY2018 · MH · contact PI
Administrative Core$146,181
P01 · FY2018 · MH · contact PI
JHU NIMH Center for Novel Therapeutics for HIV-associated Cognitive Disorders$1,522,051
P30 · FY2017 · MH · contact PI
'Intranasal Insulin Therapy for HIV- Associated Neurocognitive Disorders'$1,379,046
P01 · FY2017 · MH · contact PI
Translational Research in Neuro-AIDS and Mental Health$236,201
R25 · FY2017 · MH · contact PI
Administrative Core$183,869
P30 · FY2017 · MH · contact PI
Administrative Core$147,621
P01 · FY2017 · MH · contact PI
'Intranasal Insulin Therapy for HIV- Associated Neurocognitive Disorders'$1,404,266
P01 · FY2016 · MH · contact PI
Center for Novel Therapeutics for HIV-Associated Cognitive Disorders$808,353
P30 · FY2016 · MH · contact PI
Translational Research in Neuro-AIDS and Mental Health$236,201
R25 · FY2016 · MH · contact PI
Administrative Core$149,031
P01 · FY2016 · MH · contact PI
Center for Novel Therapeutics for HIV-Associated Cognitive Disorders$1,616,710
P30 · FY2015 · MH · contact PI
'Intranasal Insulin Therapy for HIV- Associated Neurocognitive Disorders'$1,062,066
P01 · FY2015 · MH · contact PI
Translational Research in Neuro-AIDS and Mental Health$243,761
R25 · FY2015 · MH · contact PI
Administrative Core$188,640
P30 · FY2015 · MH · contact PI
Administrative Core$150,415
P01 · FY2015 · MH · contact PI
Center for Novel Therapeutics for HIV-Associated Cognitive Disorders$1,646,237
P30 · FY2014 · MH · contact PI
Translational Research in Neuro-AIDS and Mental Health$231,254
R25 · FY2014 · MH · contact PI
Administrative Core$200,206
P30 · FY2014 · MH · contact PI
Training Clinician Scientists in Neuroinfectious Disease$180,538
T32 · FY2014 · NS · contact PI
Center for Novel Therapeutics for HIV-Associated Cognitive Disorders$1,610,453
P30 · FY2013 · MH · contact PI
Translational Research in Neuro-AIDS and Mental Health$220,927
R25 · FY2013 · MH · contact PI
Administrative Core$190,899
P30 · FY2013 · MH · contact PI
Training Clinician Scientists in Neuroinfectious Disease$110,271
T32 · FY2013 · NS · contact PI
Effect of Antiviral CNS Penetration on CSF/Blood Cytokines and Depression in HIV$77,760
R03 · FY2013 · MH
Center for Novel Therapeutics for HIV-Associated Cognitive Disorders$1,713,678
P30 · FY2012 · MH · contact PI
Translational Research in Neuro-AIDS and Mental Health$228,895
R25 · FY2012 · MH · contact PI
Administrative Core$200,393
P30 · FY2012 · MH · contact PI
Training Clincian Scientists in Neuroinfectious Disease$186,798
T32 · FY2012 · NS · contact PI
Center for Novel Therapeutics for HIV-Associated Cognitive Disorders$89,939
P30 · FY2012 · MH · contact PI
Effect of Antiviral CNS Penetration on CSF/Blood Cytokines and Depression in HIV$81,000
R03 · FY2012 · MH
Administrative Core$17,989
P30 · FY2012 · MH · contact PI
Center for Novel Therapeutics for HIV-Associated Cognitive Disorders$1,749,848
P30 · FY2011 · MH · contact PI
Translational Research in Neuro-AIDS and Mental Health$231,821
R25 · FY2011 · MH · contact PI
Administrative Core$219,697
P30 · FY2011 · MH · contact PI
Training Clincian Scientists in Neuroinfectious Disease$185,684
T32 · FY2011 · NS · contact PI
Novel Therapeutics HIV-associated Cognitive Disorders$82,616
P30 · FY2011 · MH · contact PI
Novel Therapeutics HIV-associated Cognitive Disorders$1,288,239
P30 · FY2010 · MH · contact PI
Clinical Outcomes Core$643,486
P30 · FY2010 · MH · contact PI
Surragate Markers Core$400,154
P30 · FY2010 · MH · contact PI
Developmental Core$244,599
P30 · FY2010 · MH · contact PI
Translational Research in Neuro-AIDS and Mental Health$240,370
R25 · FY2010 · MH · contact PI
Training Clincian Scientists in Neuroinfectious Disease$117,310
T32 · FY2010 · NS · contact PI
Identification of Biomarkers for HIV-Associated neurocognitive Disorders and Subs$33,226
P20 · FY2010 · DA · contact PI
Novel Therapeutics HIV-associated Cognitive Disorders$1,523,077
P30 · FY2009 · MH · contact PI
Center for Novel Therapeutics for HIV Associated Cognitive Disorders-Animal Core$1,043,591
P30 · FY2009 · MH · contact PI
Clinical Outcomes Core$771,613
P30 · FY2009 · MH · contact PI
Surragate Markers Core$462,931
P30 · FY2009 · MH · contact PI
Developmental Core$288,533
P30 · FY2009 · MH · contact PI
Identification of Biomarkers for HIV-Associated neurocognitive Disorders and Subs$32,871
P20 · FY2009 · DA · contact PI
Novel Therapeutics HIV-associated Cognitive Disorders$1,175,971
P30 · FY2008 · MH · contact PI
Clinical Outcomes Core$563,444
P30 · FY2008 · MH · contact PI
Clinical Outcomes Core$563,444
P30 · FY2008 · MH · contact PI
Developmental Core$422,824
P30 · FY2008 · MH · contact PI
Developmental Core$422,824
P30 · FY2008 · MH · contact PI
Surragate Markers Core$322,298
P30 · FY2008 · MH · contact PI
Surragate Markers Core$322,298
P30 · FY2008 · MH · contact PI
Novel Therapeutics HIV-associated Cognitive Disorders$132,595
P30 · FY2008 · MH · contact PI
Novel Therapeutics HIV-associated Cognitive Disorders$1,307,051
P30 · FY2007 · MH · contact PI
Clinical Outcomes Core$716,312
P30 · FY2007 · MH · contact PI
Predicting progression of NeuroAIDS$593,487
R01 · FY2007 · NS · contact PI
Surragate Markers Core$387,105
P30 · FY2007 · MH · contact PI
Developmental Core$203,634
P30 · FY2007 · MH · contact PI
(CHARTER) CNS HIV ANTI-RETROVIRAL THERAPY EFFECTS RESEARCH STUDY$111,774
M01 · FY2007 · RR · contact PI
PREDICTING PROGRESSION OF NEURO-AIDS$33,778
M01 · FY2007 · RR · contact PI
TISSUE AND CELL RESERVOIRS FOR HIV$22,725
M01 · FY2007 · RR · contact PI
RISK FACTORS FOR HIV-SENSORY NEUROPATHIES$18,732
M01 · FY2007 · RR · contact PI
Novel Therapeutics HIV-associated Cognitive Disorders$1,250,000
P30 · FY2006 · MH · contact PI
Predicting progression of NeuroAIDS$600,628
R01 · FY2006 · NS · contact PI
Clinical Outcomes Core$532,921
P30 · FY2006 · MH · contact PI
HIV-sensory neuropathies:risk factors, immunopathology$529,808
R01 · FY2006 · NS · contact PI
Surragate Markers Core$313,823
P30 · FY2006 · MH · contact PI
Administrative Core$224,703
P30 · FY2006 · MH · contact PI
Developmental Core$178,553
P30 · FY2006 · MH · contact PI
CNS HIV ANTI-RETROVIRAL THERAPY EFFECTS RESEARCH STUDY$142,902
M01 · FY2006 · RR · contact PI
RISK FACTORS FOR HIV-SENSORY NEUROPATHIES$86,480
M01 · FY2006 · RR · contact PI
TISSUE AND CELL$37,967
M01 · FY2006 · RR · contact PI
PREDICTING PROGRESSION OF NEURO-AIDS$30,057
M01 · FY2006 · RR · contact PI
STUDY TO EVALUATE THE EFFICACY AND SAFETY OF PROSAPTIDE$13,182
M01 · FY2006 · RR · contact PI
STUDY OF NGX-4010 TREATMENT OF PAINFUL HIV-ASSOC DISTAL SYMMETRICAL POLYNEUROPAT$6,328
M01 · FY2006 · RR · contact PI
ACTG A5157$3,164
M01 · FY2006 · RR · contact PI
ACTG 736$1,055
M01 · FY2006 · RR · contact PI
Predicting progression of NeuroAIDS$645,628
R01 · FY2005 · NS
HIV-sensory neuropathies:risk factors, immunopathology$525,047
R01 · FY2005 · NS
CNS HIV ANTI-RETROVIRAL THERAPY EFFECTS RESEARCH STUDY$158,788
M01 · FY2005 · RR
STUDY TO EVALUATE THE EFFICACY AND SAFETY OF PROSAPTIDE$143,768
M01 · FY2005 · RR
RISK FACTORS FOR HIV-SENSORY NEUROPATHIES$92,269
M01 · FY2005 · RR
STUDY OF NGX-4010 TREATMENT OF PAINFUL HIV-ASSOC DISTAL SYMMETRICAL POLYNEUROPAT$43,630
M01 · FY2005 · RR
TISSUE AND CELL$14,306
M01 · FY2005 · RR
ACTG 736$8,583
M01 · FY2005 · RR
HIV-sensory neuropathies:risk factors, immunopathology$508,104
R01 · FY2004 · NS
Predicting progression of NeuroAIDS$408,750
R01 · FY2004 · NS
RISK FACTORS FOR HIV-SENSORY NEUROPATHIES$64,119
M01 · FY2004 · RR
HIV-sensory neuropathies:risk factors, immunopathology$50,000
R01 · FY2004 · NS
CNS HIV ANTI-RETROVIRAL THERAPY EFFECTS RESEARCH STUDY$28,360
M01 · FY2004 · RR
STUDY TO EVALUATE THE EFFICACY AND SAFETY OF PROSAPTIDE$11,920
M01 · FY2004 · RR
ACTG 736$2,877
M01 · FY2004 · RR
A5117$1,233
M01 · FY2004 · RR
HIV-sensory neuropathies:risk factors, immunopathology$491,710
R01 · FY2003 · NS
HIV-sensory neuropathies:risk factors, immunopathology$488,808
R01 · FY2002 · NS
VIRAL LOAD AND IMMUNE ACTIVATION MARKERS$282,412
P01 · FY2002 · NS
VIRAL LOAD AND IMMUNE ACTIVATION MARKERS$282,412
P01 · FY2002 · NS
ANTIVIRAL ADHERANCE AND RESISTANCE IN CNS HIV INFECTION$220,513
P01 · FY2002 · NS
RESEARCH CENTERS FOR AIDS DEMENTIA$100,000
P01 · FY2002 · NS
LEXIPAFANT IN HIV DEMENTIA--TOLERABILITY AND SAFETY, PLACEBO CONTROLLED$0
M01 · FY2002 · RR
TRIAL OF LAMICTAL IN ADULT HIV PERIPHERAL NEUROPATHY$0
M01 · FY2002 · RR
LiDOCAINE GEL FOR PAINFUL PERIPHERAL NEUROPATHY IN HIV$0
M01 · FY2002 · RR
RANDOMIZED, DOUBLE BLIND, PARALLEL GROUP PLACEBO STUDY OF CPI-1189$0
M01 · FY2002 · RR
LAMOTRIGINE IN TREATMENT OF PAINFUL HIV ASSOCIATED SENSORY NEUROPATHY$0
M01 · FY2002 · RR
ACTG 291--PHASE II DOUBLE BLIND TRIAL OF RECOMBINANT HUMAN NERVE GROWTH FACTOR$0
M01 · FY2002 · RR
VIRAL LOAD AND IMMUNE ACTIVATION MARKERS$282,412
P01 · FY2001 · NS
ANTIVIRAL ADHERANCE AND RESISTANCE IN CNS HIV INFECTION$220,513
P01 · FY2001 · NS
RESEARCH CENTERS FOR AIDS DEMENTIA$163,500
P01 · FY2001 · NS
ACTG 291--PHASE II DOUBLE BLIND TRIAL OF RECOMBINANT HUMAN NERVE GROWTH FACTOR$0
M01 · FY2001 · RR
TRIAL OF LAMICTAL IN ADULT HIV PERIPHERAL NEUROPATHY$0
M01 · FY2001 · RR
LiDOCAINE GEL FOR PAINFUL PERIPHERAL NEUROPATHY IN HIV$0
M01 · FY2001 · RR
RANDOMIZED, DOUBLE BLIND, PARALLEL GROUP PLACEBO STUDY OF CPI-1189$0
M01 · FY2001 · RR
LAMOTRIGINE IN TREATMENT OF PAINFUL HIV ASSOCIATED SENSORY NEUROPATHY$0
M01 · FY2001 · RR
LEXIPAFANT IN HIV DEMENTIA--TOLERABILITY AND SAFETY, PLACEBO CONTROLLED$0
M01 · FY2001 · RR
RESEARCH CENTERS FOR AIDS DEMENTIA$764,337
P01 · FY2000 · NS
VIRAL LOAD AND IMMUNE ACTIVATION MARKERS$301,612
P01 · FY2000 · NS
ANTIVIRAL ADHERANCE AND RESISTANCE IN CNS HIV INFECTION$142,887
P01 · FY2000 · NS
ANTIVIRAL ADHERANCE AND RESISTANCE IN CNS HIV INFECTION$142,887
P01 · FY2000 · NS
RESEARCH CENTERS FOR AIDS DEMENTIA$61,087
P01 · FY2000 · NS
TRIAL OF LAMICTAL IN ADULT HIV PERIPHERAL NEUROPATHY$0
M01 · FY2000 · RR
RANDOMIZED, DOUBLE BLIND, PARALLEL GROUP PLACEBO STUDY OF CPI-1189$0
M01 · FY2000 · RR
LAMOTRIGINE IN TREATMENT OF PAINFUL HIV ASSOCIATED SENSORY NEUROPATHY$0
M01 · FY2000 · RR
LEXIPAFANT IN HIV DEMENTIA--TOLERABILITY AND SAFETY, PLACEBO CONTROLLED$0
M01 · FY2000 · RR
ACTG 291--PHASE II DOUBLE BLIND TRIAL OF RECOMBINANT HUMAN NERVE GROWTH FACTOR$0
M01 · FY2000 · RR
LiDOCAINE GEL FOR PAINFUL PERIPHERAL NEUROPATHY IN HIV$0
M01 · FY2000 · RR